Pharmaceutical Technology

NOVEMBER 4, 2022

The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise. The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise. at closing.

In-Vivo 130

In-Vivo In-Vitro Genetics Drugs 130

Drug Discovery World

APRIL 24, 2024

Evotec will identify best-in-class small molecules targeting a key fibrotic pathway with strong genetic support identified by Variant Bio and progress the programme towards the selection of a clinical development candidate(s) using its R&D platform.

Development 52

Development In-Vivo In-Vitro Genome 52

Drug Discovery World

JULY 21, 2023

BioIVT has acquired PrecisionMed, a supplier of human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics.

In-Vitro 52

In-Vitro Containment Genetics Research 52

Drug Discovery World

NOVEMBER 22, 2022

In this App Note you will learn: How Charles River Laboratories characterised the phenotype of a human iPSC-derived Huntington’s disease model from bit.bio over 38 days in vitro with high-density microelectrode arrays from MaxWell Biosystems.

In-Vitro 52

In-Vitro Genetics Scientist Drugs 52

Drug Discovery World

NOVEMBER 22, 2022

Download this new App Note from bit.bio to learn: How Charles River Laboratories characterised the phenotype of a human iPSC-derived Huntington’s disease model from bit.bio over 38 days in vitro with high-density microelectrode arrays from MaxWell Biosystems. Download the App Note now.

Research 52

Research In-Vitro Genetics Scientist 52

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene. One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene.

RNA 52

RNA Genetics Gene In-Vitro 52

Drug Discovery World

FEBRUARY 6, 2024

Catherine Brownstein is an Assistant Professor in Pediatrics at Harvard Medical School and the Assistant Director of the Molecular Genetics Core Facility at Boston Children’s Hospital. Her current work focuses on advancing the fields of genome sequencing and analysis, with an emphasis on identifying complex structural variation.

Genome 59

Genome Genomics Genetics In-Vitro 59

XTalks

MARCH 27, 2024

In vitro diagnostics, or IVD, is a field where precision, reliability and robust partnerships propel advancement. Each diagnostic evaluation and every lab discovery signify not only technological advancement but also the fruit of integrated teamwork, with decisions made collaboratively. Their significance in the field of IVD is paramount.

Manufacturing 108

Manufacturing Clinical Trials Clinical Trials In-Vitro 108

pharmaphorum

NOVEMBER 1, 2022

Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Director, Genetic Medicine. Website: [link].

RNA 52

RNA Genetics Gene Editing In-Vitro 52

Scienmag

AUGUST 31, 2020

The project seeks to kickstart the development of an open access “Organoid Cell Atlas” By creating well-characterized in vitro […].

In-Vitro 98

In-Vitro Research Development Bioinformatics 98

pharmaphorum

JUNE 24, 2022

Fujifilm’s Irvine Scientific unit has licensed rights to an artificial intelligence-powered technology developed to improve the success rate of in vitro fertilisation (IVF) techniques. “Development and testing of applications to support the selection of oocytes, sperm, and genetic assessment are in progress,” he added.

In-Vitro 52

In-Vitro Licensing Licensing Genetics 52

XTalks

DECEMBER 28, 2023

XTALKS WEBINAR: Impacts of the New IVD Regulation (IVDR) for Manufacturers and Users Live and On-Demand: Tuesday, January 9, 2024, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn how the new In Vitro Diagnostic Regulation (IVDR) impacts manufacturers and users of diagnostic devices.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

Drug Discovery World

JULY 10, 2023

This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. As a result, model generation is an attractive option often considered in parallel. An example project (Fig.

Genetics 52

Genetics Gene Editing Genetic Engineering In-Vitro 52

pharmaphorum

JANUARY 22, 2021

According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works. The UK strain – known as B.1.1.7

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

The Pharma Data

MAY 17, 2021

The European Commission’s Medical Device Coordination Group (MDCG) sent a notice to in vitro diagnostic (IVD) makers and their authorized representatives reminding them of their obligation to assess the impact of COVID-19 variants on the performance of their tests. . © 2021 Regulatory Affairs Professionals Society.

In-Vitro 52

In-Vitro Manufacturing Vaccination Vaccine 52

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Key Benefits of Attending: • Discuss the uses of advanced cell technologies to construct in vitro models of human tissues. Workshop Leader: Wendy Rowan, Scientific Director, Novel Human Genetics, GSK.

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

Drug Discovery World

JUNE 19, 2023

Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. Cystic fibrosis is a progressive genetic disease that affects the lungs, pancreas and other organs.

Development 52

Development Life Science In-Vivo In-Vitro 52

STAT News

FEBRUARY 23, 2023

Ovarian cancer has long been one of the deadliest cancers to strike women. No tests are available to detect it early, so most patients are diagnosed in later stages, when the cancer is more likely to have spread. Fewer than half of women survive 5 years past their diagnosis, and 80 percent have no known risk factors.

Genetics 111

Genetics In-Vitro Research Gene 111

Drug Discovery World

JUNE 30, 2023

Select mature stem cell lines can then be used in small-scale in vitro assays, and proven biochemical and phenotypic screens supporting target validation and deconvolution studies. Through the use of human induced pluripotent stem cells (iPSCs) derived cells, we can improve translation and reduce risk of clinical failure.

Development 52

Development Drugs In-Vitro Gene Therapy 52

FDA Law Blog

NOVEMBER 28, 2023

Gibbs — Shortly before the Thanksgiving holiday, FDA announced with no fanfare that it would be holding a Molecular and Clinical Genetics Panel meeting this Wednesday November 29. It is well known in the industry that FDA has been skeptical of multi-cancer (sometimes also referred to as pan-cancer) tests.

In-Vitro 64

In-Vitro Genetics Regulation Development 64

Bioengineer

JANUARY 16, 2024

Another genetic change at the C797 residue in the ATP binding region of EGFR’s exon 20 has emerged as a key mechanism of resistance to osimertinib. The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. months vs. 15.2 months, p = 0.01). months, 95% CI 1.3,

Genome 119

Genome Genomics Protein In-Vitro 119

The Pharma Data

MAY 3, 2021

The division served as the rapporteur in the effort to update the International Council for Harmonisation (ICH) E14 and S7B guidelines on the clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential and leads research for the Comprehensive in vitro Proarrhythmia Assay initiative.

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials In-Vivo 52

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. With over 150 pharma services/supply companies and 19 universities, Scotland is one of the most advanced life science sectors in the UK and the world. There are various other phenomics projects currently ongoing.

Research 52

Research Drugs In-Vitro Insulin 52

FDA Law Blog

MAY 25, 2022

Javitt — On April 19, FDA issued a safety communication regarding genetic non-invasive prenatal screening, commonly referred to as non-invasive prenatal tests or NIPT ( here ). NIPT are intended to screen for genetic abnormalities in a fetus. Nor is this the first time that FDA has raised concerns with NIPT.

Regulation 40

Regulation Genetics In-Vitro Development 40

The Pharma Data

APRIL 7, 2021

today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. A mutation of p53 is present in half of solid tumor cancers and is the most common genetic change identified so far in human cancers. The assay is now available for all markets accepting the CE Mark.

In-Vitro 52

In-Vitro Antibody Genetics Protein 52

The Pharma Data

DECEMBER 22, 2020

This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. “We are truly excited and humbled to bring the power of diagnostic microarray testing to the Japanese market. About Agilent Technologies.

Genome 40

Genome Genomics Genetics In-Vitro 40

FDA Law Blog

DECEMBER 6, 2023

For example, one of the primary articles cited by FDA to show poor laboratory performance of LDTs has been the subject of a reanalysis by the College of American Pathologists that found “excellent laboratory performance” of molecular oncology proficiency testing for cancer-associated genetic variants. FDA seems unconcerned by this prospect.

Regulation 59

Regulation Genetics Cosmetics Compliance 59

Drug Discovery World

JANUARY 23, 2023

This action sensitised GBM cells to radiotherapy both in vitro and in vivo (in mouse models). “Our research has revealed cladribine as a radiosensitiser for GBM treatment by drug repurposing, which can offer multiple advantages,” says Prof Youn. “As GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

The Pharma Data

DECEMBER 22, 2020

A2’s Tmod engineered T cells uniquely combine a potent activating mechanism to kill tumor cells with a blocking mechanism that protects normal cells from harm by exploiting the loss of genetic material in tumors. A2 will also receive from Merck an equity investment and reimbursement of certain expenses. Series B in October.

Development 52

Development Engineer Manufacturing In-Vitro 52

FDA Law Blog

JULY 8, 2021

Javitt — For many years, one of the most controversial topics in device regulation has been the dual-track oversight of in vitro diagnostics (IVDs) and laboratory developed tests (LDTs). According to Concert Genetics there are currently an estimated 160,000 genetic tests – which is only one type of LDT.

Regulation 52

Regulation In-Vitro Production Genetics 52

XTalks

APRIL 6, 2022

The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Photo source: Inivata. Lung cancer is the most common cancer in men and the third most common cancer in women, according to global lung cancer statistics by the World Cancer Research Fund.

DNA 105

DNA In-Vitro Doctors Doctor 105

pharmaphorum

OCTOBER 29, 2020

The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.

Development 45

Development DNA In-Vitro Genome 45

Drug Discovery World

MAY 9, 2023

Mice and humans share the same set of organs and over 85% of their genetic makeup, which enables researchers to study interdependent biological consequences of genetic variation and clinical responses to anti-cancer compounds before advancing to human clinical trials. Cancer is far more complex than the sum of its parts.

Development 52

Development Drugs In-Vivo Clinical Trials 52

Roots Analysis

JANUARY 14, 2024

It is worth mentioning that in vitro gene expression requires a suitable host for the production of a specific gene product. Notably, biologics have higher success rates than conventional small-molecule drugs owing to lesser off-target toxicity of biologics, which is one of the key reasons of failures in small molecule drugs development.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

Pharma Mirror

APRIL 21, 2024

This represents an increasingly promising field of precision medicine, holding significant prospects for preventing and treating numerous challenging or genetic diseases. In vitro transcribed (IVT) mRNA has been successfully The post General Design Methods for mRNA Drugs appeared first on Pharma Mirror Magazine.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

pharmaphorum

DECEMBER 15, 2022

The month of November saw a number of notable hires and personnel moves in biotech and pharma. Read on for a round-up of some of the biggest moves that crossed our desks. Boehringer Ingelheim taps new head of medicine. AstraZeneca hires new SVP for EUCAN. New CEO in at Angelini Pharma. More CEO shakeups.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

XTalks

MARCH 28, 2024

In the healthcare community, March is recognized globally to be Endometriosis Awareness Month. This year’s theme is “Innovation and Hope.” This growth can occur on the ovaries, fallopian tubes, the outer surface of the uterus or other organs in the pelvis. This condition is known to affect an estimated one in ten women of reproductive age.

Hormones 40

Hormones Life Science In-Vitro Drugs 40